Express Pharma

JULY 27, 2024

India’s pharmaceutical industry has emerged as a global powerhouse, earning the moniker ‘pharmacy of the world’. This remarkable journey is underpinned by a complex interplay of factors, including robust R&D, skilled manpower, and a conducive regulatory environment. However, the industry now stands at a critical juncture, grappling with the intricate issue of Intellectual Property Rights (IPR) protection.

Pharmaceutical Companies 84

Pharmaceutical Companies Pharmaceutical Companies Drug Pricing Drug Development 84

Drug Patent Watch

JULY 27, 2024

This chart shows the pharmaceutical companies with the most patents in South Africa. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

PharmaTech

JULY 27, 2024

Scorpius Holdings is set to launch its first CGMP manufacturing campaign at its San Antonio, Texas, facility for mammalian cell culture in the 2024 third quarter.

52

52

Drug Patent Watch

JULY 27, 2024

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.

52

52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

Pharmacy Times

JULY 27, 2024

One of the most important drivers of a patients’ uncontrolled hypertension is medication nonadherence.

49

49

Drug Patent Watch

JULY 27, 2024

Annual Drug Patent Expirations for NASCOBAL Nascobal is a drug marketed by Par Pharm and Endo Pharms Inc and is included in two NDAs. It is available from one supplier.

52

52

Drug Patent Watch

JULY 27, 2024

Annual Drug Patent Expirations for RETEVMO Retevmo is a drug marketed by Loxo Oncol Eli Lilly and is included in two NDAs. It is available from one supplier.

52

52